MAGIC PROJECT

Accelerating Development of Genetic Therapies for Muscular Dystrophies

GOAL

The primary goal is to develop precise gene therapies using cutting-edge technologies, such as muscle-on-chip devices, focusing on muscular dystrophies.

VISION

The MAGIC Project envisions a future where transformative gene therapies provide effective treatment for people living with rare muscular dystrophies.

MISSION

To accelerate genetic therapy development through advanced models, aiming to overcome barriers and impact the lives of people with muscular dystrophy.

magic-horizon.eu
info@magic-horizon.eu
@MAGIC_Horizon

ABOUT US

Led by **Prof. Francesco Saverio Tedesco** from University College London and The Francis Crick Institute, along with the support of **Prof. Mario Amendola** from Inserm and the Genethon Institute, the MAGIC consortium consists of partners from 9 countries, including academic institutions and research hospitals, small and medium-sized enterprises and charitable organisations.

WHY THIS PROJECT?

Current treatments for muscular dystrophies are limited, and there is a lack of clinical evidence for the efficacy of gene therapy. The project aims to fill this gap by pioneering advanced models and innovative genetic interventions to transform the treatment landscape for these severe genetic disorders.

Create

Create precise models for gene therapies in rare neuromuscular conditions.

Engineer

Develop specialized muscle-on-chip devices for assessing novel gene therapies.

Explore

Advanced gene editing strategies for effective and patient-centered translation.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union and HADEA.

This work is funded by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee grant numbers 10080927, 10079726, 10082354 and 10078461.

This work has received funding from the Swiss State Secretariat Funding for Education, Research and Innovation (SERI).